New Delhi: There is no significant benefit from the use of plasma. This is the verdict by ICMR.
On Monday, the government revised the clinical guidance for Covid-19 treatment, dropping the off-label use of convalescent plasma as it was not found beneficial in reducing the progression to severe disease or death. Late Monday advisory from the National Task Force of the Indian Council of Medical Research (ICMR), along with experts from the Health Ministry, periodically updates guidelines on recommended modes of treatment. Registered Doctors anywhere, however, aren’t bound by the Task Force recommendations.
Though a trial by the ICMR on 400 patients last year — called the PLACID trial — had found no significant benefit from the use of plasma it continued to find a place in the recommended guidelines, in ‘off label’ use.Several other international trials had also found no benefit from plasma therapy.
In fact, some experts have said the use of such plasma may have even played a role in the facilitating new worrisome mutations to the virus.
Discussion about this post